Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 47.15 -6.85% -3.47
EGRX closed down 6.85 percent on Friday, March 22, 2019, on 89 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical EGRX trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Multiple of Ten Bearish Other 0.00%
Mar 21 Crossed Above 20 DMA Bullish -6.85%
Mar 21 180 Bullish Setup Bullish Swing Setup -6.85%
Mar 21 Multiple of Ten Bullish Other -6.85%
Mar 21 Outside Day Range Expansion -6.85%
Mar 21 Upper Bollinger Band Touch Strength -6.85%
Mar 20 Fell Below 20 DMA Bearish -1.55%
Mar 18 Crossed Above 20 DMA Bullish -4.11%

Older signals for EGRX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.
Medicine Chemistry Pharmaceutical Organic Chemistry Lymphoma Chronic Lymphocytic Leukemia Lung Cancer Direct Thrombin Inhibitors Heparin Induced Thrombocytopenia Injectable Products Nitrogen Mustards Organochlorides Treatment Of Chronic Lymphocytic Leukemia
Is EGRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 85.66
52 Week Low 36.03
Average Volume 208,530
200-Day Moving Average 59.0797
50-Day Moving Average 44.4614
20-Day Moving Average 48.4295
10-Day Moving Average 48.227
Average True Range 2.0371
ADX 19.27
+DI 22.3612
-DI 16.423
Chandelier Exit (Long, 3 ATRs ) 46.7287
Chandelier Exit (Short, 3 ATRs ) 50.1513
Upper Bollinger Band 50.9107
Lower Bollinger Band 45.9483
Percent B (%b) 0.24
BandWidth 10.246647
MACD Line 1.1422
MACD Signal Line 1.3463
MACD Histogram -0.2041
Fundamentals Value
Market Cap 715.21 Million
Num Shares 15.2 Million
EPS 5.96
Price-to-Earnings (P/E) Ratio 7.91
Price-to-Sales 3.34
Price-to-Book 4.96
PEG Ratio 0.95
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 52.27
Resistance 3 (R3) 52.82 51.67 51.41
Resistance 2 (R2) 51.67 50.37 51.39 51.13
Resistance 1 (R1) 49.41 49.56 48.84 48.86 50.84
Pivot Point 48.26 48.26 47.97 47.98 48.26
Support 1 (S1) 46.00 46.96 45.43 45.45 43.46
Support 2 (S2) 44.85 46.15 44.57 43.17
Support 3 (S3) 42.59 44.85 42.89
Support 4 (S4) 42.04